Empagliflozin/linagliptin/metformin
Combination of
EmpagliflozinSGLT2 inhibitor
LinagliptinDPP-4 inhibitor
MetforminAnti-diabetic biguanide
Clinical data
Trade namesTrijardy XR
AHFS/Drugs.comProfessional Drug Facts
License data
Routes of
administration		By mouth
ATC code
Legal status
Legal status
Identifiers
KEGG

Empagliflozin/linagliptin/metformin, sold under the brand name Trijardy XR, is a drug combination used for the treatment of type 2 diabetes.[2] It is a combination of empagliflozin, linagliptin, and metformin. Empagliflozin/linagliptin/metformin was approved for use in the United States in January 2020.[3][4]

Adverse effects

To lessen the risk of developing ketoacidosis (a serious condition in which the body produces high levels of blood acids called ketones) after surgery, the FDA has approved changes to the prescribing information for SGLT2 inhibitor diabetes medicines to recommend they be stopped temporarily before scheduled surgery. Empagliflozin should each be stopped at least three days before scheduled surgery.[5]

Symptoms of ketoacidosis include nausea, vomiting, abdominal pain, tiredness, and trouble breathing.[5]

History

The combination preparation was developed and marketed by Boehringer Ingelheim Pharmaceuticals, Inc. and Eli Lilly and Company.[6][7]

References

  1. ↑ "Trijardy XR- empagliflozin, linagliptin, metformin hydrochloride tablet, extended release". DailyMed. Retrieved 24 December 2021.
  2. ↑ Kim ES, Deeks ED (September 2015). "Empagliflozin/Linagliptin: A Review in Type 2 Diabetes". Drugs. 75 (13): 1547–57. doi:10.1007/s40265-015-0457-z. PMID 26323340. S2CID 27675087.
  3. ↑ "Trijardy XR: FDA-Approved Drugs". U.S. Food and Drug Administration (FDA). Retrieved 11 February 2020.
  4. ↑ "US FDA approves only triple-combination tablet with Jardiance for adults with type 2 diabetes" (Press release). Eli Lilly and Company. 27 January 2020. Retrieved 10 February 2020 – via PR Newswire.
  5. 1 2 "FDA revises labels of SGLT2 inhibitors for diabetes to include warning". U.S. Food and Drug Administration. 19 March 2020. Retrieved 6 June 2020. Public Domain This article incorporates text from this source, which is in the public domain.
  6. ↑ "US FDA approves only triple-combination tablet with Jardiance for adults with type 2 diabetes" (Press release). Boehringer Ingelheim. 27 January 2020. Retrieved 10 February 2020.
  7. ↑ "Trijardy XR (empagliflozin, linagliptin, and metformin hydrochloride extended-release tablets), for oral use" (PDF). Boehringer Ingelheim. Retrieved 10 February 2020.
This article is issued from Wikipedia. The text is licensed under Creative Commons - Attribution - Sharealike. Additional terms may apply for the media files.